Tarsons Products Limited (NSE:TARSONS)
217.95
+6.92 (3.28%)
May 22, 2026, 3:29 PM IST
Tarsons Products Revenue
In the fiscal year ending March 31, 2026, Tarsons Products had annual revenue of 4.47B INR with 13.83% growth. Tarsons Products had revenue of 1.28B in the quarter ending March 31, 2026, with 13.17% growth.
Revenue
4.47B
Revenue Growth
+13.83%
P/S Ratio
2.61
Revenue / Employee
4.93M
Employees
906
Market Cap
11.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.47B | 542.71M | 13.83% |
| Mar 31, 2025 | 3.92B | 960.20M | 32.40% |
| Mar 31, 2024 | 2.96B | 131.46M | 4.64% |
| Mar 31, 2023 | 2.83B | -175.46M | -5.83% |
| Mar 31, 2022 | 3.01B | 694.77M | 30.04% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 584.62B |
| Cipla | 277.12B |
| Apollo Hospitals Enterprise | 252.29B |
| Divi's Laboratories | 105.60B |
| Remus Pharmaceuticals | 8.60B |
| Ind-Swift Laboratories | 5.94B |
| GPT Healthcare | 4.73B |
| Beta Drugs | 3.96B |